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Abstract
Background: Although recent models suggest that the detection of Circulating Tumor Cells (CTC) in epithelial-
to-mesenchymal transition (EM CTC) might be related to disease progression in metastatic breast cancer (MBC)
patients, current detection methods are not efficient in identifying this subpopulation of cells. Furthermore, the
possible association of EM CTC with both clinicopathological features and prognosis of MBC patients has still to
be demonstrated. Aims of this study were: first, to optimize a DEPArray-based protocol meant to identify,
quantify and sort single, viable EM CTC and, subsequently, to test the association of EM CTC frequency with
clinical data.
Methods: This prospective observational study enrolled 56 MBC patients regardless of the line of treatment.
Blood samples, depleted of CD45pos leukocytes, were stained with an antibody cocktail recognizing both epithelial and
mesenchymal markers. Four CD45neg cell subpopulations were identified: cells expressing only epithelial markers
(E CTC), cells co-expressing epithelial and mesenchymal markers (EM CTC), cells expressing only mesenchymal
markers (MES) and cells negative for every tested marker (NEG). CTC subpopulations were quantified as both
absolute cell count and relative frequency. The association of CTC subpopulations with clinicopathological
features, progression free survival (PFS), and overall survival (OS) was explored by Wilcoxon-Mann-Whitney test
and Univariate Cox Regression Analysis, respectively.
Results: By employing the DEPArray-based strategy, we were able to assess the presence of cells pertaining to
the above-described classes in every MBC patient. We observed a significant association between specific CD45neg
subpopulations and tumor subtypes (e.g. NEG and triple negative), proliferation (NEG and Ki67 expression) and
sites of metastatic spread (e.g. E CTC and bone; NEG and brain). Importantly, the fraction of CD45neg cells co-expressing
epithelial and mesenchymal markers (EM CTC) was significantly associated with poorer PFS and OS, computed,
this latter, both from the diagnosis of a stage IV disease and from the initial CTC assessment.
Conclusion: This study suggests the importance of dissecting the heterogeneity of CTC in MBC. Precise
characterization of CTC could help in estimating both metastatization pattern and outcome, driving clinical
decision-making and surveillance strategies.
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Background
Circulating tumor cells (CTC) are rare cells shed into
the bloodstream from primary tumors and metastases
[1]. Since these latter represent the major cause of
cancer-associated mortality [2], CTC isolation and
characterization is one of the most active areas of
translational cancer research [1]. In fact, CTC might
represent an active source of metastatic spread from a
primary tumor to secondary lesions [3, 4], and their
role as a prognostic biomarker has been robustly dem-
onstrated both in primary and metastatic cancer [5–9].
Moreover, detection and enumeration of CTC could
serve as an early marker of response to systemic ther-
apy, whereas the molecular characterization of CTC
could lead to individualized targeted treatments,
possibly sparing patients unnecessary and ineffective
therapies [10].
Current models suggest that the invasive phenotype of
breast cancers is mostly associated with an epithelial-to-
mesenchymal transition (EMT) [11]. This process leads
to the expression of mesenchymal markers on tumor
cells, which is paralleled by an increase in the migration
and invasion properties of tumor cells, as well as in their
resistance to apoptosis and ability to evade the immune
response [11]. The detection of CTC that express either
mesenchymal and epithelial mRNAs or only mesenchy-
mal mRNAs could therefore be related, in metastatic
breast cancer (MBC) patients, to disease progression
[12]. However, existing detection methods are not effi-
cient in identifying CTC in EMT. In fact, the only Food
and Drug Administration (FDA)-approved device to de-
tect CTC, the CellSearch System (Veridex, Warren, NJ,
USA), allows counting only epithelial cell adhesion mol-
ecule (EpCAM)-positive epithelial CTC. Moreover, this
device does not allow harvesting viable CTC suitable for
downstream analyses. For this reason, in the last years
several innovative strategies to enrich, detect, count,
and/or molecularly characterize CTC have been devel-
oped [13]. However, for most of these a clinical valid-
ation is still missing [14].
DEPArray (Silicon Biosystems, Bologna, Italy) is a
dielectrophoresis-based platform able to handle a rela-
tively small number of cells. The device is aimed at ana-
lyzing and sorting single, viable, rare cells thanks to an
image-based selection process and to the entrapment of
cells inside dielectrophoretic cages. Selected cells can
be individually moved by software-controlled modula-
tion of electrical fields and ultimately recovered for
downstream molecular analyses [15].
The main objectives of our study were: to develop a
novel strategy to enrich blood samples in CTC, inde-
pendently from the expression of epithelial markers; to
take advantage of the DEPArray system to identify and
sort, based on a multiparametric fluorescence analysis,
single, viable epithelial-like CTC as well as CTC in
EMT; to explore, in a prospective observational case
study including 56 patients with MBC, the association
between clinicopathological features, CTC number, and
distribution of CTC subpopulations; and, finally, to
provide evidence of the possible prognostic role of the
enumeration of CTC in EMT.
Methods
Patient population, ethics, consent, and permissions
Our prospective observational study was approved by
the Local Ethics Committee (decision No. 152/2011/
Sper) and, subsequently, by the Regional Ethics Com-
mittee (amendment No. 178/2014/Em). Fifty-six pa-
tients were enrolled by the Department of Oncology,
University Hospital of Udine, Italy. Of these, 47 blood
samples were analyzed for the presence of CTC by the
Department of Pathology, University Hospital of Udine,
Italy. Nine patients were excluded from the analysis be-
cause the volume of sampled blood was inadequate (n = 1),
the timing of blood sampling was incorrect (n = 3), or the
samples were employed to optimize the technical pro-
cedure (n = 5). All patients gave their written informed
consent before their enrollment.
Patient enrollment and follow-up
The eligibility criteria for patient recruitment were as
follows: female, adult (≥ 18 years) patients with measur-
able MBC, at the start of a new systemic therapy, with-
out limits to number and kind of previous therapies
(hormone therapy, chemotherapy, targeted therapy),
and Eastern Cooperative Oncology Group performance
status (ECOG PS) score ≤ 2. A histological sample rep-
resentative of the primary tumor had to be available.
Before starting a new treatment, patients underwent
baseline blood sampling for CTC evaluation (see later),
and standard clinical studies.
Standard Response Evaluation Criteria In Solid Tu-
mors (RECIST) criteria were used to determine patients’
responses to treatment [16].
An expert pathologist reviewed the biopsies of every
enrolled patient, defining the tumor type following the
WHO classification of breast cancer [17], grading as in
[18], and tumor subtype as in [19].
Sampling of biologic material
Blood samples of 15 ml of blood were collected from 56
MBC patients and 27 healthy donors. Ethylenediamine
tetraacetate was used as anticoagulant. The samples
were processed within 4 hours from blood withdrawal.
Healthy control blood samples were collected from fe-
male blood donors aged 20–60 years.
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Flow cytometry
Epithelial-like (ER+/PR+/HER2− MCF-7; ATCC, Tedding-
ton, Middlesex, UK) and mesenchymal-like (triple-nega-
tive MDA-MB231; ATCC, Teddington, Middlesex, UK)
breast cancer cell lines were tested by flow cytometry, to
determine their immunophenotype, employing monoclo-
nal antibodies labeled with phycoerythrin (PE), fluorescein
isothiocyanate (FITC), or allophycocyanin (APC) and di-
rected against: CD10 (BD Biosciences, San Jose, CA,
USA), CD29 (clone TS2/16; eBioscience, San Diego, CA,
USA), CD44 (clone IM7; Biolegend, San Diego, CA, USA),
CD45 (BD Pharmingen, BD Bioscience, San Jose, CA,
USA / Milenyi Biotec, Calderara di Reno, BO, Italy),
CD49a (clone TS2/7; Biolegend), CD49b (BD Pharmin-
gen), CD49d (clone 9F10; Biolegend, San Diego, CA,
USA), CD49f (clone GOH3; Biolegend, San Diego, CA,
USA), CD66e (Serotec, Oxford, UK), CD90 (clone SE10;
eBioescience), CD133 (Miltenyi Biotec), CD146 (BD Phar-
mingen), E-Cadherin (clone 67A4; Biolegend), EGFR
(clone AY13; Biolegend), EpCAM (clone 9C4; Biolegend),
human epidermal growth factor receptor 2/ HER2 (clone
24D2; Biolegend), and N-Cadherin (clone 8C11; BD
Biosciences). Isotype matched antibodies were used as
controls. Cells were analyzed employing a FACSCantoII
(BD Biosciences) flow cytometer. Differentially expressed
antigens were subsequently tested in the CD45neg fraction
(CTC enrichment; see later) of healthy donors to exclude
those able to bind circulating cells in controls.
Immunomagnetic enrichment and sample staining
procedures
Blood samples (7.5 ml) were first subjected to red blood
cell lysis, employing isotonic ammonium-chloride buf-
fer, and then incubated for 20 minutes with CD45
MicroBeads (Miltenyi Biotec). Subsequently, samples
were immunomagnetically depleted of the CD45pos
leukocyte fraction using LD separation columns in a
MACS MIDI separator (Miltenyi Biotec), according to
the manufacturer’s instructions. To evaluate the effi-
ciency and the yield of the depletion strategy, both
CD45neg and CD45pos fractions were labeled with CD45
and analyzed by fluorescence-activated cell sorting
(FACS). CD45 depleted samples were subsequently
stained with a cocktail of antibodies recognizing: epithe-
lial markers (i.e., EpCAM, E-Cad) labeled by FITC, mes-
enchymal markers (i.e., CD44, CD146, and N-Cadherin)
labeled by PE, and the pan-leukocyte CD45 marker
labeled by APC.
Spiked samples
For mimicking the in vivo presence of different subsets
of CTC in the peripheral blood of MBC patients, known
numbers of MCF-7 and MDA-MB231 cells, prelabeled
with Hoechst 33342, were spiked into 7.5 ml of blood
samples (n = 27) obtained from healthy donors. After
erythrocyte lysis and immunomagnetic depletion of
CD45pos cells, the enriched samples were stained and
analyzed by flow cytometry, as already described, to
compute the yield of recovery, sensitivity, and specificity
of the entire procedure.
Immunofluorescence analysis of intracellular markers
For immunofluorescence analysis of intracellular markers,
cells were fixed in 4% buffered paraformaldehyde, and
permeabilized with 0.1% Triton X-100. Estrogen receptor
(ER), vimentin, and cytokeratins were detected using the
following monoclonal antibodies: anti-ERα (Clone SP1;
ACZON, Monte San Pietro, BO, Italy), anti-vimentin
(Clone V9; DAKO, Glostrup, Denmark), and anti-
cytokeratins (8, 18, 19; BIO GENEX, San Ramon, CA,
USA). Alexa Fluor 555 conjugated secondary antibodies
(Invitrogen, Carlsbad, CA, USA) were used. Cells were an-
alyzed by Leica DMI6000 B (Leica Microsystems, Wetzlar,
Germany) utilizing a 40× oil immersion objective (numer-
ical aperture: 1.25).
CTC detection and sorting by the DEPArray
Blood samples, depleted of CD45pos cells, were stained
with Hoechst 33342 and the afore-described antibody
cocktail. Stained cells were resuspended in 14 μl of
RPMI1640 supplemented with 10% fetal bovine serum
and 1% antibiotics (all from Invitrogen).
Cell sorting experiments were performed by DEPArray
(Silicon Biosystems) as described in the manufacturer’s
instructions. Briefly, DEPArray cartridges (A300K) were
manually loaded with 14 μl of sample and 830 μl of cul-
ture medium. After loading the cartridge into the
DEPArray system, the sample was injected by the system
into a microchamber where the cells were exposed to an
electric field consisting of 16,000 electrical cages in
which individual cells are trapped. Image frames for each
of the four fluorescent filters (FITC, PE, APC, and 4′,6-
diamidino-2-phenylindole (DAPI)/Hoechst) and bright-
field images were captured. Cell detection was based on
a DAPI/Hoechst fluorescence threshold. For each cell, a
unique ID was assigned. Captured images were proc-
essed and presented by the CellBrowser software that
enables selection of cells of interest by the operator.
Nucleated cells negative for CD45 were chosen, inde-
pendently from the expression of epithelial and/or mes-
enchymal markers, and moved to a parking area in the
cartridge. Individual cells were then subsequently moved
to a recovery area where a last visual confirmation of cell
presence could be performed. Typically, the procedure
required about 2.5 hours for first recovery, with imaging
of four channels including bright-field, and about 15 mi-
nutes for the recovery of each cell.
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After DEPArray analysis, single tumor cells were re-
covered alive and then subjected to transcriptional ana-
lysis of target genes by multiplex reverse transcriptase
PCR (RT-PCR).
mRNA isolation and quantitative PCR analysis from
single cells
After a single cell lysis step, performed according to the
Ampli1 Whole Genome Amplification Kit (Silicon Bio-
systems) manufacturer’s instructions, the mRNA was
isolated from the sample and reverse-transcribed into
cDNA (Superscript; Invitrogen). All of the reagents re-
quired for quantitative RT-PCR were combined in a master
mix (Universal SYBR Green Master Mix; Roche, Basel,
Switzerland), including primers (Additional file 1: Table S1),
probes, and enzyme (according to the manufacturer’s
instructions). Then 14 μl aliquots of this solution and 1
μl of single-cell cDNA were dispensed in a 96-well plate.
Real-time PCR and analyses were performed, employing
a LightCycler 480 (Roche) instrument. For each amplifi-
cation reaction, the melting temperature (Tm) and Cp
values were computed.
Statistical analysis
Patients’ characteristics have been summarized by
means of descriptive analysis. Categorical variables were
described by frequency distribution, whereas continu-
ous variables were reported as median and interquartile
range. Age, performance status, and number of lines
were dichotomized, according to clinical interest, using
respectively 70 years, ECOG PS 1, and the median of
lines received (n = 2) as the threshold.
CTC subpopulation distributions were tested for
normality by Shapiro–Wilk test and their association
with clinicopathological features was explored by Wil-
coxon rank-sum test or Kruskal–Wallis test, as ap-
propriate. Owing to the exploratory purpose of the
study, no corrections for multiple comparisons were
applied. The prognostic impact of CTC count was in-
vestigated by univariate Cox regression models with
95 % confidence interval both in terms of overall sur-
vival (OS; calculated from both the stage IV diagnosis
and the initial CTC assessment) and progression-free
survival (PFS; calculated from CTC assessment to the
first evidence of disease progression or death). The
proportional hazard assumption was tested through
the Schoenfeld residuals test.
Differences between CTC distribution quartiles were
described by Kaplan–Meier estimator plot and tested
by the log-rank test. p <0.05 was considered significant.
Statistical analysis was conducted using StataCorp 2013
Stata Statistical Software: Release 13 (College Station,
Texas, USA).
Results
Patient recruitment and baseline characteristics
This study enrolled 56 MBC patients treated at the
University Hospital of Udine between March 2013 and
May 2015, regardless of the line of treatment. CTC
assessment was performed before the beginning of a
new therapeutic line. Among them, 47 patients were
eligible for CTC analysis. Table 1 summarizes patients’
clinicopathological characteristics and treatment history.
Median age was 62 years (range 36–82). The most
Table 1 Demographic and clinicopathological features of the
47 analyzed metastatic breast cancer patients
Age
Median (range) 62 (36–82)
< 70 years 36 (77 %)
≥ 70 years 11 (23 %)
ECOG PS, n (%)
0 29 (62 %)
1 14 (29 %)
2 4 (9 %)
Immunophenotype, n (%)
Luminal-like 25 (54 %)
HER2-positive 11 (23 %)
Triple negative 11 (23 %)
Histotype, n (%)
Ductal 38 (84 %)
Lobular 7 (16 %)
Metastatic sites,a n (%)
Bone 29 (62 %)
Liver 22 (47 %)
Lung 16 (34 %)
CNS 3 (6 %)
Number of metastatic sites, n (%)
1 16 (34 %)
≥ 2 31 (66 %)
Number of previous lines, n (%)
0 15 (32 %)
1 9 (19 %)
≥ 2 23 (49 %)
Type of treatments received, n (%)
Chemotherapy 33 (70 %)
Endocrine therapy 6 (13 %)
Chemotherapy and endocrine therapy 5 (11 %)
Palliative care 2 (6 %)
Anti-HER2 targeted therapy 12 (26 %)
aPatients may have more than one site involved
ECOG PS Eastern Cooperative Oncology Group Performance Status, CNS central
nervous system, HER2 human epidermal growth factor receptor 2
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common histotype was ductal (84 %), while the most fre-
quent subtype was luminal-like (54 %). MBC was diag-
nosed as de novo disease in 15 patients. The median
number of previous therapeutic lines was 1 (range 0–10).
At the time of recruitment, 66 % of patients presented at
least one visceral site of metastatic spread, while 10 % of
patients were affected by bone-only disease. At the data-
base lock, disease progression was observed in 29 cases
and death in 18 cases. Median follow-up was 33 months,
median OS from CTC assessment was 21.7 months,
while median PFS was 8.12 months. The estimated 1-
year and 2-year OS rates were 70 % and 46 %, respect-
ively, while the estimated 1-year and 2-year PFS rates
were 37 % and 19 % respectively.
Identification of epithelial and mesenchymal CTC by
means of surface antigen expression
A possible limitation of the strategies currently used for
the enumeration of CTC from blood samples is the het-
erogeneous expression of EpCAM on tumor cells, espe-
cially on those undergoing EMT [20]. In order to
circumvent this issue, we decided to adopt a CTC en-
richment strategy based on red blood cell lysis followed
by the immunomagnetic depletion of leukocytes from
blood samples (i.e., a negative selection; Fig. 1a). The
efficiency of this procedure was 99.98 ± 0.012 % (n = 8;
Fig. 1b) and an average of 2656 ± 2531 cells/7.5 ml of
processed blood (n = 6) could be recovered.
In order to prospectively identify both epithelial-like
and mesenchymal-like CTC, we evaluated the surface
antigen immunophenotype of two breast cancer lines
considered to be prototypical epithelial-like (MCF7) and
mesenchymal-like (MDA-MB231) tumor cells [21, 22].
MCF-7 and MDA-MB231 cells differed in the expression
of EpCAM, E-Cadherin, CD44, CD49f, and CD146, the
first two being upregulated in epithelial-like cells but the
latter three in mesenchymal-like cells (Fig. 1c, d). Since
our objective was to identify an antibody cocktail able to
recognize tumor cells with high specificity, we employed
flow cytometry to evaluate the expression of the candi-
date markers in the CD45-negative fraction of 10 healthy
donors. In this way we could exclude those antigens that
were commonly present in circulating cells. In fact,
while CD49f was frequently observed in donor blood
cells, E-Cadherin, EpCAM, CD146, and CD44 were al-
most undetectable in the CD45-negative fraction of fe-
male donors (Fig. 1e). Therefore, we tested, in spiked
donor samples subjected to negative selection, an anti-
body cocktail recognizing epithelial (i.e., FITC-labeled
anti-EpCAM, and anti-E-Cad), mesenchymal (i.e. PE-
labeled anti-CD44, and anti-CD146), and leukocyte (i.e.,
APC-labeled anti-CD45) markers. This strategy was able
to identify, in spiked samples (n = 27), Hoechst-labeled
breast cancer cells with a sensitivity of 99 ± 1.4 %, a
specificity of 99 ± 0.7 %, and a positive predictive value
of 95 ± 5.7 %. Values were similar for epithelial-like
breast tumor cells (99.7 ± 0.4 %, 98.4 ± 2 %, 90 ± 2.6 %)
and mesenchymal-like breast tumor cells (98 ± 1.7 %,
99.9 ± 0.1 %, 99.9 ± 0.1 %) (Fig. 1f ). To further confirm
the specificity of the cocktail, this latter was tested in the
CD45-negative fraction of 18 female donors; no epithe-
lial cells were detected, while cells expressing only mes-
enchymal markers were documented, at low number, in
three samples (Additional file 2: Table S2A).
Enumeration and sorting of viable single CTC by
DEPArray technology
We took advantage of the DEPArray system to identify
and sort single, viable CTC, based on a multipara-
metric fluorescence analysis. Specifically, spiked sam-
ples containing epithelial-like and/or mesenchymal-like
breast tumor cells were stained with Hoechst 33342
and the afore-described antibody cocktail. This ap-
proach allowed us to identify and sort single breast
tumor cells as viable nucleated cells, negative for CD45
and expressing epithelial and/or mesenchymal markers
(Fig. 2a). Sorted cells were suitable for RNA isolation
followed by real-time PCR analysis of transcripts typ-
ical of epithelial and EMT cells (Fig. 2b).
Once the isolation protocol was optimized, we ana-
lyzed blood samples obtained from enrolled patients. In
this case, to the afore-described antibody cocktail we
added N-Cadherin, a marker of EMT [23] not expressed
on human CD45neg cells (Fig. 1e). On the basis of the
DEPArray analysis, CD45-negative cells were classified
as epithelial CTC (expressing only epithelial markers (E
CTC)), CTC in EMT (coexpressing epithelial and mes-
enchymal markers (EM CTC)), putative mesenchymal
cells (expressing only mesenchymal markers (MES)), and
negative cells (not expressing the tested markers (NEG)).
Raw data are presented in Additional file 3: Table S3.
All of these cell types could be detected and sorted
(Fig. 2c and Table 2). Specifically, the median number
of 96 CD45neg cells per 7.5 ml of peripheral blood was
counted. Of these, more than 2/3 were expressing only
mesenchymal markers, 4 % were negative for all of the
tested antibodies, and a median fraction of 16 % was
positive for the analyzed epithelial markers. Of these
latter cells, positive to the epithelial cocktail and there-
fore considered as bona fide CTC, 22 % coexpressed
mesenchymal markers. When the same protocol was
applied to blood samples obtained from three female
donors, no E CTC, EM CTC, and MES cells were de-
tected (Additional file 2: Table S2B), confirming the ab-
sence of bona fide CTC in healthy donors. Conversely,
NEG cells were documented in all samples, although at
a low number (Additional file 2: Table S2B).
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Fig. 1 (See legend on next page.)
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Downstream mRNA analysis supported the classifica-
tion based on the surface immmunophenotype. Specif-
ically, single sorted epithelial cells did not express
vimentin, while cells in EMT expressed both vimentin
and cytokeratin 19, and mesenchymal cells expressed
vimentin only. Additionally, in patient-derived E CTC,
the expression of HER2 and ER transcripts could also
be demonstrated (Fig. 2d).
Altogether these findings indicate that the DEPArray-
based CTC detection protocol we optimized could identify
CTC subsets in clinical samples obtained from MBC pa-
tients. Importantly, the collection of viable, single CTC
followed by gene expression analysis corroborates our
classification based on cell surface immunophenotype.
Association between CTC subpopulations and
clinicopathological features
Next, we assessed the association between the clinico-
pathological characteristics of MBC patients and the dif-
ferent subtypes of circulating cells that were identified,
as already described, by DEPArray (Table 3, Fig. 3).
Patients affected by HER2-positive disease, with re-
spect to those affected by HER2-negative disease, had a
significantly lower number of MES cells (p = 0.022),
EM CTC (both in absolute number and in percentage,
p = 0.029 and p = 0.035, respectively), ETOT CTC (p =
0.037), and CD45neg (p = 0.046). Intriguingly, patients
affected by triple-negative disease showed, with respect
to those affected by other profiles, a significantly higher
proportion and absolute number of NEG cells (p =
0.024 and p = 0.033, respectively). The presence of
bone metastases was significantly associated with an
increase in the absolute number of E CTC (p = 0.0074)
and EM CTC (p = 0.024) and with both the absolute
number (p = 0.0058) and the percentage (p = 0.00060)
of CTC expressing epithelial markers (irrespective of
the expression of mesenchymal markers (ETOT CTC)).
Additionally, bone metastases were associated with a
lower percentage of MES cells (p = 0.012), while patients
with liver localizations were characterized by a higher pro-
portion of E CTC (p = 0.011). Of note, patients with cen-
tral nervous system involvement were characterized by a
higher number of circulating NEG cells, both when
considered as absolute numbers (p = 0.016) and as a per-
centage (p = 0.020). A higher absolute number of negative
cells was also associated with highly proliferating primary
breast tumors (Ki67 ≥ 14%; p = 0.039).
Interestingly, even if marginally significant, a lower
percentage of MES cells was observed among patients
with liver localizations and CNS involvement.
The number of metastatic sites did not seem to influence
the number or proportion of different CTC populations.
Altogether these results indicate that important clin-
ical features of MBC patients are associated with distinct
subpopulations of circulating cells. Therefore, the in-
depth characterization of CD45neg cells may be endowed
with a prognostic or predictive significance.
Exploration of the prognostic role of CTC
Lastly, we evaluated whether the enumeration of CD45neg
subpopulations by the DEPArray system could predict
outcome.
Univariate Cox regression analysis showed a prognos-
tic role of both ETOT CTC and EM CTC, as a continu-
ous percentage variable, in terms of both OS from
stage IV diagnosis (p = 0.015 and p = 0.022, respectively)
and from CTC assessment (p = 0.013 and p = 0.0016, re-
spectively). However, the proportion of EM CTC was
the only parameter that resulted to be significantly as-
sociated with PFS (p = 0.016). Intriguingly, the propor-
tion of MES/CD45neg had a favorable impact in terms
of OS (from stage IV diagnosis p = 0.037). The full set
of variables investigated in the univariate analysis is re-
ported in Table 4.
Furthermore, we assessed that stratifying the MBC
population according to the percentage of EM CTC and
MES could help in describing prognosis. The resulting
Kaplan–Meier estimator plots are shown in Fig. 4.
Altogether these results indicate that the identification
of the subpopulation of E CTC coexpressing mesenchy-
mal markers may help in discriminating the subset of
patients that are at high risk for disease progression.
Discussion
Over the last 10 years, a general consensus has been
reached on the role exerted by the quantitative analysis
(See figure on previous page.)
Fig. 1 CTC enrichment strategy. a Scheme showing the enrichment strategy. b Dot plots showing physical parameters (i) and CD45 expression of
cells before (ii) and after depletion (iii), (iv). CD45-positive (iii) and CD45-negative (iv) fractions are shown. c Immunofluorescence analysis of
the epithelial-like (MCF7, left panels) and mesenchymal-like (MDA-MB231, right panels) breast cancer cell lines showing cytokeratin (green fluorescence)
and vimentin (red fluorescence) expression. Nuclei are labeled by DAPI (blue fluorescence). d FACS analysis showing, in histograms, the differential expression
of epithelial and mesenchymal surface antigens by MCF-7 (green histograms) and MDA-MB231 (red histograms) cell lines. White histograms
show negative controls. e Histograms showing the estimated number of CD45-negative peripheral blood mononuclear cells, isolated from 7.5 ml of
healthy blood female donors (n = 10), expressing either epithelial or mesenchymal antigens. f FACS plot showing the ability of the enrichment strategy
to identify MCF7 and MDA-MB231 cells spiked into healthy donor peripheral blood samples. DAPI 4',6-diamidino-2-phenylindole, EpCAM
epithelial cell adhesion molecule. (Color figure online), FSC forward scatter, SSC side scatter, MFI mean fluorescence intensity
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of CTC in the prognostic stratification of patients with
MBC [1, 5, 8]. As a consequence, it has been suggested
to employ CTC as a liquid biopsy to perform real-time
monitoring of the metastatic status of a given patient
[24], possibly offering an important parameter for preci-
sion medicine and personalized treatments [25].
The only FDA-approved instrument for the enumer-
ation of CTC is, thus far, the CellSearch System (Veri-
dex) [26]. Although this latter is robust and its ability to
predict patients’ prognosis has been validated over the
years [5, 8, 27], several potential limitations have been
described. Specifically, the CellSearch System processes
fixed blood samples and selects CTC from blood cells
relying on the expression of EpCAM on their surface.
However, several investigators [28, 29] have raised con-
cerns regarding the homogeneous expression of this
antigen on CTC. This issue is especially prominent in
cells undergoing EMT, a process that downregulates
typical epithelial markers (such as EpCAM, E-Cadherin,
and keratins), upregulates mesenchymal markers (e.g.
vimentin), and is characterized by reduced adhesive
properties and increased invasiveness [20]. To overcome
this major intrinsic limitation of the methodology, in
recent years several investigators have tried to develop
alternative assays that either target antigens alternative
to EpCAM (e.g., CD146, CD49f) [29–31] or take advan-
tage of different, antigen-independent, techniques (e.g.,
PCR-based assays, density gradient centrifugation, cell
filtration) [1, 20]. However, the latter techniques, still at
an experimental stage, are not approved for diagnostic
purposes because they lack a clinical validation [14].
Fig. 2 Enumeration and sorting of viable single CTC by DEPArray
technology. a Image gallery of MDA-MB231 and MCF-7 cells, analyzed
from a spiked sample, showing, from top to bottom, two cells
coexpressing mesenchymal (red fluorescence) and epithelial (green
fluorescence) markers, one cell expressing only mesenchymal
markers, and one cell expressing only epithelial markers, respectively.
Images of tumor cell morphology are shown in the bright-field
channel (grey), while cell nuclei are stained by Hoechst (blue). b
Real-time PCR showing cytokeratin-19 and vimentin expression in
sorted, single MCF-7 (green line) and MDA-MB231 (red line) cells. c
Representative images of the analysis of a blood sample from a
MBC patient enriched employing the strategy described in Fig. 1a.
The CD45-depleted fraction was labeled with antibodies recognizing
epithelial (green fluorescence) and mesenchymal (red fluorescence)
markers, as well as the common leukocyte antigen CD45 (cyan
fluorescence). The image bar displays, from top to bottom, one
cell expressing only epithelial markers (E CTC), one cell coexpressing
mesenchymal and epithelial markers (EM CTC), one cell expressing
only mesenchymal markers (MES), one CD45-positive leukocyte
(LEUK), and one cell negative for all of the tested markers (NEG),
respectively. Images of tumor cell morphology are shown in the
bright-field channel (grey), while cell nuclei are stained by Hoechst
(blue). d Real-time PCR showing cytokeratin-19, vimentin, HER2,
and ER expression in sorted, single E-CTC (green line), EM-CTC
(red line), and MES (blue line) cells (Color figure online)
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In this work, we have optimized an alternative enrich-
ment strategy, taking into account that, as previously
stated, the “perfect” CTC marker should be expressed on
all CTC, but not on autochthonous blood cells [1]. There-
fore, we first depleted leukocytes employing anti-CD45
immunomagnetic beads. Subsequently, we selected the
antibody cocktail that showed the best performance in
discriminating epithelial and mesenchymal surface an-
tigens on CTC. For this purpose we screened 17 anti-
gens to identify those that were differentially expressed
by a luminal-like cell line (i.e., MCF7) and a triple
negative-like cell line (i.e., MDA-MB231). Candidate
antigens were further refined to exclude those that
were expressed on circulating, CD45neg cells, in female
blood donors. This way we decided that, as opposed to
a previous report [31], CD49f was not a useful marker
in our hands. Employing this strategy, we were able to
sort with high reproducibility breast cancer cells from
spiked samples.
Another possible limitation of the CellSearch System
is its inability to sort single, viable, and unfixed CTC to
perform further downstream analyses. To circumvent
this problem, we employed a dielectrophoresis-based
system [32] (i.e., the DEPArray system) that has the
ability to perform fluorescence microscopy analysis,
mobilization, and collection of single viable cells from a
pool of up ≈ 100,000 cells. In our hands, the labeling
strategy that we optimized was a perfect match for the
DEPArray system. In fact, the immunodepletion ap-
proach resulted in a number of recovered cells that was
compatible with the loading capacity of the DEPArray
chip (but avoids the loss of cells that do not express
EpCAM), and the multiparametric analysis, based on
an antibody cocktail recognizing both epithelial and
mesenchymal antigens, allowed the identification of
different cell subtypes. Last, our approach permitted us
to isolate single, viable CTC [33] that could be further
analyzed by quantitative RT-PCR. As a result, however,
our method of analysis is slower than the method
employed by the CellSearch System. In fact, with the
workflow for sample preparation and analysis sug-
gested in the manuscript, two patients per day can be
processed. However, we can obtain, for each analyzed
patient, an improved evaluation of the CTC heterogen-
eity, and molecular studies of single sorted CTC might
add valuable prognostic and predictive information. By
systematically applying our analysis to 47 blood sam-
ples obtained from MBC patients, we observed four
different cell subpopulations: CTC expressing only epi-
thelial antigens, CTC coexpressing epithelial and mes-
enchymal antigens, cells expressing only mesenchymal
antigens, and cells that do not express either epithelial
or mesenchymal antigens. While the first two cell types
are obviously CTC, less clear is the neoplastic nature of
the latter two cell types. Ongoing single-cell genomic ana-
lysis experiments will clarify this issue (data not shown).
However, the more in-depth analysis of the CD45neg
fraction has allowed us to identify specific circulating
cell subsets that are significantly associated with relevant
clinical parameters. In fact, we showed that different
breast tumor subtypes are associated with a distinct pat-
tern of circulating CD45neg cell subpopulations. Add-
itionally, we observed that HER2-positive tumors were
characterized by a trend to a reduced number of circu-
lating MES and ETOT CTC. This finding is in line with
data obtained by Cristofanilli’s group [34] and could
Table 2 CD45neg subpopulations at baseline
Cell class Immunophenotype Median (25th; 75th)
E CTCa E+M− 8 (3; 24)
EM CTCa E+M+ 3 (0; 9)
MESa E−M+ 45 (15; 95)
NEGa E−M− 4 (0; 14)
Derived parameters Function Median (25th; 75th)
ETOT CTCa EM CTC + E CTC 10 (4; 33)
CD45nega ETOT CTC +MES + NEG 96 (42; 145)
EM CTC fraction over CD45neg b EM CTC/CD45neg × 100 2 (0; 8)
ETOT CTC fraction over CD45neg b ETOT CTC/CD45neg × 100 16 (5; 30)
MES fraction over CD45neg b MES/CD45neg × 100 79 (40; 88)
NEG fraction over CD45neg b NEG/CD45neg × 100 4 (0; 15)
Summary of the definition of the cell subpopulations counted by DEPArray, the parameters computed from these absolute cell numbers, and the descriptive
statistics, expressed as median and interquartile range, of cell classes and derived parameters (n = 47)
aResults expressed as absolute number of cells for 7.5 ml of peripheral blood
bResults expressed as percentage
E reactivity to the epithelial antibody cocktail, E CTC subset of CD45neg expressing only epithelial markers, EM CTC subset of CD45neg coexpressing mesenchymal
and epithelial markers, ETOT CTC CD45neg cells expressing epithelial markers independently from the expression of mesenchymal markers, M reactivity to the
mesenchymal antibody cocktail, MES subset of CD45neg expressing mesenchymal markers only, NEG subset of CD45neg negative to the antibody cocktail
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Table 3 Association between circulating CD45neg subpopulations and clinicopathological features of MBC patients
Absolute number Fraction over CD45neg (%)
E CTC EM CTC ETOT CTC MES NEG CD45neg EM CTC ETOT CTC MES NEG
Tumor characteristics
HER2 Positive (N = 11) 3 (0; 9) 0 (0; 3) 3 (1; 12) 22 (6; 42) 0 (0; 14) 42 (19; 118) 0 (0; 3) 16 (4; 25) 81 (33; 97) 0 (0; 38)
Negative (N = 36) 8 (4; 27) 4 (0; 13) 15 (5; 35) 80 (15; 124) 4 (0; 13) 102 (60; 153) 4 (0; 14) 17 (6; 39) 74 (40; 88) 4 (0; 15)
p* 0.12 0.029 0.037 0.022 0.84 0.046 0.035 0.37 0.70 0.94
Profile Luminal (N = 25) 8 (4; 32) 4 (1; 15) 16 (6; 53) 72 (14; 103) 0 (0; 9) 97 (59; 197) 4 (0; 14) 19 (6; 55) 70 (39; 90) 0 (0; 6)
HER2-positive (N = 11) 3 (0; 9) 0 (0; 3) 3 (1; 12) 22 (6; 42) 0 (0; 14) 42 (19; 118) 0 (0; 3) 16 (4; 25) 81 (33; 96) 0 (0; 38)
TNBC (N = 11) 9 (2; 24) 3 (0; 9) 15 (2; 30) 84 (29; 125) 9 (5; 18) 124 (60; 150) 2 (0; 8) 16 (3; 21) 79 (60; 86) 15 (4; 16)
p** 0.30 0.044 0.087 0.052 0.092 0.12 0.064 0.35 0.93 0.056
Ki-67 <14 % (N = 10) 7 (4; 35) 7 (0; 18) 18 (6; 53) 42 (6; 103) 0 (0; 4) 76 (41; 197) 4 (0; 31) 19 (8; 63) 63 (37; 90) 0 (0; 5)
≥14 % (N = 34) 8 (2; 16) 2 (0; 6) 10 (3; 30) 55 (20; 92) 8 (0; 18) 99 (42; 138) 2 (0; 7) 16 (5; 25) 77 (41; 86) 8 (0; 16)
p* 0.45 0.15 0.37 0.64 0.039 0.74 0.33 0.39 0.90 0.087
Metastatic site
Bone Yes (N = 29) 10 (4; 32) 4 (0; 15) 20 (7; 52) 45 (14; 84) 2 (0; 12) 95 (48; 126) 5 (0; 14) 25 (14; 55) 60 (33; 81) 2 (0; 14)
No (N = 29) 4 (1; 6) 0 (0; 4) 5 (1; 12) 55 (20; 129) 6 (0; 18) 89 (23; 150) 0 (0; 2) 7 (3; 16 85 (75; 90) 6 (0; 16)
p* 0.0072 0.024 0.0058 0.34 0.43 0.97 0.0096 0.0006 0.012 0.48
Liver Yes (N = 22) 9 (4; 27) 3 (0; 9) 15 (4; 45) 42 (15; 75) 6 (0; 14) 90 (41; 126) 3 (0; 14) 25 (10; 55) 63 (33; 84) 4 (0; 15)
No (N = 25) 6 (1; 10) 3 (0; 9) 10 (2; 21) 84 (20; 123) 3 (0; 12) 103 (42; 156) 2 (0; 6) 9 (3; 19) 81 (58; 89) 2 (0; 15)
p* 0.28 0.99 0.27 0.28 0.87 0.47 0.48 0.011 0.067 0.86
Lung Yes (N = 16) 9 (4; 20) 1 (0; 6) 10 (6; 30) 57 (23; 126) 6 (0; 13) 87 (42; 153) 3 (0; 14) 12 (4; 30) 79 (49; 87) 5 (0; 16)
No (N = 31) 6 (2; 27) 3 (0; 15) 10 (3; 45) 45 (10; 92) 3 (0; 14) 95 (23; 135) 0 (0; 6) 17 (6; 33) 75 (33; 89) 2 (0; 15)
p* 0.69 0.23 0.86 0.26 0.71 0.72 0.16 0.36 0.50 0.74
CNS Yes (N = 3) 24 (8; 47) 6 (0; 21) 45 (8; 53) 45 (30; 75) 43 (14; 90) 126 (97; 180) 6 (0; 12) 25 (6; 55) 31 (25; 60) 34 (14; 50)
No (N = 44) 6 (2; 20) 3 (0; 9) 10 (3; 32) 53 (15; 100) 3 (0; 12) 85 (37; 143) 2 (0; 10) 16 (5; 32) 79 (40; 89) 2 (0; 15)
p* 0.16 0.56 0.26 1.0000 0.016 0.26 0.75 0.51 0.082 0.020
Number of sites 1 (N = 16) 5 (2; 9) 1 (0; 10) 7 (2; 17) 55 (13; 93) 1 (0; 9) 82 (41; 122) 2 (0; 9) 9 (3; 21) 82 (47; 91) 1 (0; 14)
≥ 2 (N = 31) 9 (3; 27) 3 (0; 9) 15 (4; 36) 45 (15; 123) 5 (0; 14) 97 (41; 156) 2 (0; 12) 19 (6; 36) 70 (37; 86) 5 (0; 16)
p* 0.22 0.76 0.19 0.84 0.40 0.67 0.78 0.16 0.28 0.61
Results are expressed as median (25th, 75th percentile). Bold cells indicate significant (p <0.05) differences as detected by Wilcoxon rank-sum test (*) or Kruskal-Wallis test (**), as appropriate
E CTC subset of CD45neg expressing epithelial markers only, EM CTC subset of CD45neg coexpressing mesenchymal and epithelial markers, ETOT CTC CD45neg cells expressing epithelial markers independently from the
expression of mesenchymal markers, MBC metastatic breast cancer, MES subset of CD45neg expressing mesenchymal markers only, NEG subset of CD45neg negative to the antibody cocktail, CNS central nervous system,










Fig. 3 (See legend on next page.)
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possibly be related to the targeted therapy to which the
MBC patient population is exposed. In fact, it has been
shown that herceptin can downregulate the expression
of chemokine (C-X-C motif ) receptor 4 (CXCR4), which
is required for HER2-enhanced invasion, migration,
and metastasis [35]. Conversely, triple-negative tumors,
with respect to the luminal ones, were associated with
an increased absolute number and relative number of
circulating cells not expressing either mesenchymal or
epithelial markers. This evidence suggests that a frac-
tion of CTC not recognized by the antibody cocktail
that we employed may be comprised in this cell subset.
Importantly, our approach allowed us to sort this cell
population, which is now available for downstream mo-
lecular analyses. Ongoing DNA sequencing experiments
will verify the presence of mutations shared with the
tumor of origin, while future gene expression profiling ex-
periments will help in selecting additional surface proteins
that could be used to further refine our procedure.
Concerning the association between metastatic sites
and the CD45neg cell subsets, an increased number of
NEG cells was significantly associated with the presence
of brain secondary lesions. This result is in line with lit-
erature data showing that CTC with brain metastatic po-
tential are indeed EpCAM-negative [4] and supports the
importance of going beyond the pure enumeration of
CTC expressing this antigen. Conversely, bone metasta-
ses were strongly associated with the absolute and rela-
tive abundance of CTC expressing epithelial antigens.
This finding is consistent with the observed association
of bone metastases with a CTC number ≥ 5 cells/7.5 ml
of peripheral blood, as estimated by CellSearch [36].
Last, we assessed whether the identification of CTC in
EMT was endowed with a prognostic significance. Spe-
cifically, the fraction of CD45neg cells coexpressing epi-
thelial and mesenchymal markers was associated with
both computed patient PFS and OS, the latter both from
the diagnosis of stage IV disease and from the CTC
(See figure on previous page.)
Fig. 3 Association between CTC subpopulations and clinicopathological characteristics. Box and whiskers plots showing median, interquartile
ranges, 5th and 95th percentile of the absolute number or frequency of different classes of cells (E, E/M, MES, NEG) significantly associated with
specific clinicopathological features. E CTC cells expressing only epithelial markers, EM CTC cells coexpressing mesenchymal and epithelial markers,
ETOT CTC CD45neg cells expressing epithelial markers, independently from the expression of mesenchymal markers, MES cells expressing only
mesenchymal markers, NEG cells negative for all of the tested markers, CNS central nervous system, HER2 human epidermal growth factor
receptor 2
Table 4 Univariate analysis of demographic data, clinicopathological data, and circulating CD45neg subpopulations with PFS and OS,
computed from both the diagnosis of metastasis and the CTC assessment
Variable OS (from stage IV diagnosis) OS (from CTC assessment) PFS
HR 95 % CI p HR 95 % CI p HR 95 % CI p
ECOG PS 2-3 vs. 0-1 5.288 1.392–20.096 0.015 11.294 2.467–51.702 0.0018 2.558 0.730–8.963 0.14
BC profile HER2-positive vs. luminal 0.338 0.075–1.525 0.16 0.274 0.061–1.235 0.092 0.616 0.237–1.599 0.32
TNBC vs. luminal 1.803 0.564–5.771 0.32 0.972 0.312–3.029 0.96 1.212 0.495–2.963 0.67
Lines received > 2 vs. < 2 3.452 1.138–10.475 0.029 0.622 0.245–1.581 0.32 0.557 0.265–1.172 0.12
Age ≥ 70 vs. < 70 0.593 0.19–1.809 0.34 0.652 0.213–1.997 0.45 1.031 0.459–2.314 0.94
E CTC (n) 1.003 0.982–1.024 0.79 1.001 0.980–1.023 0.92 1.004 0.989–1.020 0.6
EM CTC (n) 1.018 0.994–1.043 0.13 1.023 0.998–1.049 0.08 1.020 0.998–1.043 0.081
ETOT CTC (n) 1.006 0.993–1.019 0.35 1.006 0.993–1.019 0.38 1.007 0.996–1.018 0.24
MES (n) 0.998 0.991–1.005 0.56 0.998 0.991–1.005 0.56 0.998 0.992–1.003 0.41
NEG (n) 0.998 0.981–1.015 0.79 0.992 0.975–1.010 0.41 0.997 0.986–1.008 0.58
CD45neg (n) 0.999 0.994–1.004 0.79 0.999 0.993–1.004 0.61 0.999 0.995–1.003 0.56
EM CTC/CD45neg (%) 1.022 1.003–1.042 0.022 1.035 1.013–1.057 0.0016 1.021 1.004–1.039 0.016
E TOT/CD45neg (%) 1.019 1.004–1.034 0.015 1.019 1.004–1.034 0.013 1.010 0.997–1.023 0.12
MES/CD45neg (%) 0.984 0.968–0.999 0.037 0.988 0.973–1.002 0.1 0.993 0.981–1.005 0.26
NEG/CD45neg (%) 0.999 0.972–1.027 0.95 0.992 0.966–1.018 0.54 0.998 0.980–1.017 0.86
Bold cells indicate significant (p <0.05) association as detected by univariate Cox regression model
CI confidence interval, CTC circulating tumor cells, ECOG PS Eastern Cooperative Oncology Group Performance Status, E CTC subset of CD45neg expressing
epithelial markers only, EM CTC subset of CD45neg coexpressing mesenchymal and epithelial markers, ETOT CTC CD45neg cells expressing epithelial markers
independently from the expression of mesenchymal markers, HR hazard ratio, MES subset of CD45neg expressing mesenchymal markers only, NEG subset of
CD45neg negative to the antibody cocktail, OS overall survival, PFS progression-free survival, BC breast cancer, HER2 human epidermal growth factor receptor 2,
TNBC triple negative breast cancer
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assessment. We decided to evaluate the overall survival
from both enrollment into the study and from the diag-
nosis of metastasis, because, conceptually, these are the
expression of two different views. The first considers the
cancer as characterized by a site-dependent and time-
related tumor heterogeneity that can be caused by both
intrinsic (tumor-related) and extrinsic (therapy-related)
factors [37], and CTC analyses have been considered a
way to perform real-time monitoring of the metastatic
disease by means of a minimally invasive technique
(liquid biopsy) [20]. Upon the second view, CTC mea-
surements could predict the intrinsic drug resistance of
the metastatic disease. In our prospective observational
study, the ability of CTC in EMT to predict the OS from
the diagnosis of the metastatic disease suggests the exist-
ence of a subset of tumors whose prognosis is not
significantly modified by currently available therapies. A
similar conclusion has been reached by the clinical study
SWOG S0500 [38], where early switching to an alternate
cytotoxic therapy in patients with persistently increased
CTC after 21 days of first-line chemotherapy was not ef-
fective in prolonging OS. Those authors suggested that
it would be more profitable for this population of pa-
tients to be recruited into prospective trials of novel
therapies and to take advantage of molecular analyses of
metastasis, CTC, or circulating cell-free DNA to guide
therapy [38].
It is important to underline that because of the rela-
tively small sample size, the results from this observa-
tional study must be treated cautiously. Accordingly,
validation of these findings in a larger independent co-
hort of patients is needed.
Fig. 4 Survival curves. a Kaplan–Meier estimator plots in terms of OS from stage IV diagnosis (upper panel), OS from CTC assessment (middle
panel), and PFS (lower panel) in patients with MBC for those with a fraction of EM CTC above the 75th percentile (dotted red line) and for those
with a fraction of EM CTC less than or equal to the 75th percentile (solid black line) before initiation of a new line of therapy. b Kaplan–Meier
estimates in terms of OS from stage IV diagnosis (upper panel), OS from CTC assessment (middle panel), and PFS (lower panel) in patients with
MBC for those with a fraction of MES above the 50th percentile (dotted green line) and for those with a fraction of MES less than or equal to the
50th percentile (solid orange line) before initiation of a new line of therapy. CTC circulating tumor cells, OS overall survival, PFS progression-free
survival. (Color figure online)
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Conclusions
In this work we optimized a novel strategy to enrich
blood samples in CTC, independent from the expression
of epithelial markers. Moreover, taking advantage of the
DEPArray system, we have identified and sorted, based
on multiparametric fluorescence analysis, single, viable
epithelial-like CTC as well as CTC in EMT. Intriguingly,
our CTC enrichment strategy allowed us to observe two
additional circulating subsets in the CD45neg fraction:
one expressing only mesenchymal surface proteins, and
the other negative for all of the tested markers. The neo-
plastic nature of these cell populations is still an open
issue. Nonetheless, each of these CD45neg cell subsets
was associated, in a prospective study including 47 pa-
tients affected by MBC, with clinically relevant parame-
ters, such as tumor subtype, Ki67 expressions and the
site of metastasis. Most importantly, the fraction of CTC
expressing EMT markers was an independent predictor
of poor outcome.
Altogether these results indicate that the protocol that
we optimized for the analysis and sorting of circulating
CD45neg cells in MBC patients could be of high clinical
relevance and deserves validation in a larger independ-
ent cohort of patients.
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